All-case registration surveillance for people who receive HEMLIBRA

Trial Profile

All-case registration surveillance for people who receive HEMLIBRA

Planning
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Mar 2018 New trial record
    • 23 Mar 2018 According to a Chugai Pharmaceutical media release, results of the surveillance will be reported to the regulatory authorities, and the data shall be announced at future scientific meetings.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top